全文获取类型
收费全文 | 2454篇 |
免费 | 139篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 74篇 |
妇产科学 | 54篇 |
基础医学 | 210篇 |
口腔科学 | 41篇 |
临床医学 | 385篇 |
内科学 | 316篇 |
皮肤病学 | 42篇 |
神经病学 | 212篇 |
特种医学 | 184篇 |
外科学 | 149篇 |
综合类 | 246篇 |
一般理论 | 2篇 |
预防医学 | 231篇 |
眼科学 | 37篇 |
药学 | 188篇 |
中国医学 | 76篇 |
肿瘤学 | 162篇 |
出版年
2023年 | 11篇 |
2022年 | 24篇 |
2021年 | 51篇 |
2020年 | 39篇 |
2019年 | 29篇 |
2018年 | 38篇 |
2017年 | 52篇 |
2016年 | 55篇 |
2015年 | 69篇 |
2014年 | 108篇 |
2013年 | 130篇 |
2012年 | 127篇 |
2011年 | 170篇 |
2010年 | 126篇 |
2009年 | 114篇 |
2008年 | 152篇 |
2007年 | 139篇 |
2006年 | 119篇 |
2005年 | 108篇 |
2004年 | 86篇 |
2003年 | 81篇 |
2002年 | 73篇 |
2001年 | 65篇 |
2000年 | 50篇 |
1999年 | 51篇 |
1998年 | 38篇 |
1997年 | 34篇 |
1996年 | 32篇 |
1995年 | 23篇 |
1994年 | 16篇 |
1993年 | 18篇 |
1992年 | 27篇 |
1991年 | 36篇 |
1990年 | 27篇 |
1989年 | 37篇 |
1988年 | 32篇 |
1987年 | 32篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 27篇 |
1983年 | 13篇 |
1982年 | 11篇 |
1981年 | 18篇 |
1980年 | 11篇 |
1978年 | 10篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 11篇 |
1970年 | 5篇 |
1969年 | 5篇 |
排序方式: 共有2638条查询结果,搜索用时 15 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
3.
Gahan J Pandina Robert Bilder Philip D Harvey Richard S E Keefe Michael G Aman Georges Gharabawi 《Neuropsychopharmacology》2007,62(3):226-234
BACKGROUND: Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed. METHODS: Data from two 6-week, double-blind, placebo-controlled studies (n = 228) were combined, as were three 1-year, open-label studies (n = 688). Patients with DBDs and subaverage IQ, 5 to14 years, received placebo or risperidone .02 to .06 mg/kg/day. Cognitive measures included the Continuous Performance Task (CPT) and Verbal Learning Test for Children (VLT-C). Efficacy was assessed using the Nisonger Child Behavior Rating Form (NCBRF). Adverse events were collected via spontaneous report; sedation was assessed using visual analog scale. RESULTS: Improvements on the NCBRF Conduct Problem subscale were significantly greater for risperidone- versus placebo-treated patients (-15.8 vs. -6.4, p < .0001) in short-term studies; significant reductions were observed in long-term studies (-16.3, p < .0001). No overall decline and some significant improvement in attention (CPT) and memory (VLT-C) were noted regardless of treatment in short-term studies. VLT-C improved significantly (p < .0001) for both groups, with no difference between treatment groups. Improvements in memory (VLT-C) and attention (CPT) were noted in long-term studies. Somnolence/sedation did not affect cognitive function. CONCLUSIONS: Cognitive function was not altered by risperidone in short-term studies and was maintained or improved with one year of treatment in children with DBDs and subaverage IQ, potentially representing age-appropriate gains. 相似文献
4.
HA Carpay P Matthijsse M Steinbuch PGH Mulde 《Cephalalgia : an international journal of headache》1997,17(5):591-595
In an open, randomized cross-over study in 124 patients, we compared the efficacy, safety and patient preference of oral and subcutaneous sum triptan in the acute treatment of migraine. Patients were treated for 3 attacks or 3 months and then crossed over. Primary clinical efficacy was defined as a reduction in headache severity on a four-point self-rating scale from severe (3) or moderate (2) to mild (1) or none (0), or mild (1) to none (0). Efficacy was evaluated 2 h after the administration of subcutaneous and 4h after the administration of oral sumatriptan. Subcutaneous sumatriptan was significantly more effective than oral sumatriptan in relieving headache (over all three attacks 78% vs 61% improvement), improving clinical disability (55% vs 41 % improvement) and relieving nausea (69% vs 53%), vomiting (72% vs 32%) and phono- or photophobia (67% vs 49%). Median time to recurrence was shorter after subcutaneous (12.5 h) than after oral sumatriptan (18 h); the number of patients experiencing a recurrence was similar Patients reported more adverse events after subcutaneous sumatriptan (1.32 per attack) than after the oral form (0.85 per attack), but all adverse events were mild to moderate in intensity and of short duration. Patient opinion was more often positive after subcutaneous sumatriptan. These results may be useful in counselling patients to choose between the available marketed formulations of sumatriptan. 相似文献
5.
M R Keefe 《ANS. Advances in nursing science》1988,10(3):70-78
Conceptually weak and unsubstantiated theories attempting to explain the origins of infant colic have led to inconsistent and ineffective approaches to the management of the infant with persistent crying. A new theoretical perspective that views excessive crying as a developmental behavioral disorder is presented. The clinical implications of this model for nurses working with families of irritable infants are discussed. 相似文献
6.
7.
8.
Behavioral and cognitive-behavioral approaches to chronic pain are receiving increasing attention from researchers and clinicians. This article reviews and highlights recent research advances and future research directions. Assessment research reviewed includes studies examining the social context of pain, the relationship of chronic pain to depression, cognitive variables affecting pain, and comprehensive assessment measures. Treatment outcome studies reviewed are those evaluating the effects of behavioral and cognitive-behavioral treatments for chronic pain. These studies focus on comparisons of behavioral treatment with control conditions, comparisons of two behavioral treatments, and prevention of chronic pain. Future directions for assessment and treatment research are outlined. 相似文献
9.
P D Harvey M F Lenzenweger R S Keefe D L Pogge M R Serper R C Mohs 《Psychiatry research》1992,44(2):141-151
Male schizophrenic patients (n = 142) were examined with a clinical assessment of their language dysfunctions with the Scale for the Assessment of Thought, Language, and Communication (TLC). Confirmatory factor analyses were conducted to test the relative fit of several differential theoretical models of the factorial structure of thought disorders. The models examined were positive-negative thought disorder, a three-factor model based on the results of an earlier exploratory factor analysis, and a simpler verbal productivity-disconnection model that can be extracted from other exploratory analyses and empirical studies. The positive-negative thought disorder model failed to fit the data, while the three-factor model fit the data, but no better than the simpler verbal productivity-disconnection model. 相似文献
10.
超细β-磷酸三钙/聚-L-乳酸复合材料的制备与骨折内固定器的加工 总被引:3,自引:0,他引:3
目的:制备分散性良好的超细β-磷酸三钙(β-TCP)/聚-L-乳酸(PLLA)复合材料及新型可吸收骨折内固定器。方法:通过研磨方法制备β-TCP超细粒子,用一缩二乙二醇作分散剂研磨β-TCP后,再将β-TCP与PLLA超声混合,制得复合材料,经注塑加工制成可吸收骨钉,并采用扫描电镜等方法进行表征。结果与结论:用一缩二乙二醇作分散剂研磨β-TCP后再经超声混合,可以使β-TCP超细粒子在复合材料中分散均匀,粒子大小仅为300nm左右,β-TCP与PLlA基体之间结合良好。超细β-TCP/PLLA复合材料可加工成可吸收骨钉,弯曲强度达到100MPa左右,完全满足松质骨内固定的要求。 相似文献